Ernexa Therapeutics released FY2024 Q4 earnings on March 12 (EST), actual revenue USD 1K, actual EPS USD -2.2553

Brief Summary

On March 12, 2025 (US Eastern Time), Ernexa Therapeutics reported its fiscal year 2024 fourth-quarter results, posting negligible revenue of $1,000 alongside a net loss of $5,767,000, which translates to a loss per share of $2.2553.

Impact of The News

Analysis of Ernexa Therapeutics’ Q4 2024 Financial Results